Singh Parmvir, Wolfe Scott P, Alloo Allireza, Gottesman Silvija P
Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
J Cutan Pathol. 2020 Jan;47(1):65-69. doi: 10.1111/cup.13562. Epub 2019 Aug 25.
Checkpoint inhibition has become an important target in the management of malignant melanoma. As anti-CTLA4 inhibitors and anti-PD1 antibodies are increasingly utilized, reports of immune-related adverse events (IRAEs) are becoming more frequent. Common noted cutaneous IRAEs are morbilliform, lichenoid, bullous, granulomatous, psoriasiform, and eczematous eruptions. We report a case of interstitial granulomatous dermatitis and granulomatous arteritis in the setting of nivolumab (anti-PD1) monotherapy for metastatic melanoma. There are many different causes for granulomatous vasculitis, such as herpes virus infection, lymphoproliferative disorders, systemic vasculitis, and inflammatory bowel disease. This report adds to the growing literature on granulomatous IRAEs due to checkpoint inhibition.
检查点抑制已成为恶性黑色素瘤治疗中的一个重要靶点。随着抗CTLA4抑制剂和抗PD1抗体的使用越来越多，免疫相关不良事件（IRAEs）的报告也越来越频繁。常见的皮肤IRAEs表现为麻疹样、苔藓样、大疱性、肉芽肿性、银屑病样和湿疹样皮疹。我们报告了1例在使用纳武单抗（抗PD1）单药治疗转移性黑色素瘤过程中出现的间质性肉芽肿性皮炎和肉芽肿性动脉炎病例。肉芽肿性血管炎有许多不同的病因，如疱疹病毒感染、淋巴增殖性疾病、系统性血管炎和炎症性肠病。本报告增加了有关因检查点抑制导致肉芽肿性IRAEs的文献。
